Nakagawa Kazuo, Yotsukura Masaya, Mimae Takahiro, Hattori Aritoshi, Miyoshi Tomohiro, Isaka Mitsuhiro, Endo Makoto, Tsutani Yasuhiro, Isaka Tetsuya, Maniwa Tomohiro, Nakajima Ryu, Yoshioka Hiroshige, Takei Hidefumi, Aokage Keiju, Watanabe Shun-Ichi
Department of Thoracic Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Department of Thoracic Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
Jpn J Clin Oncol. 2024 Dec 7;54(12):1237-1243. doi: 10.1093/jjco/hyae100.
The Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG) was organized in 1986 and initially included 26 collaborative institutions, which has increased to 52 institutions currently. JCOG-LCSSG includes thoracic surgeons, medical oncologists, pathologists, and radiotherapists. In the early period, the JCOG-LCSSG mainly focused on combined modality therapies for lung cancer. Since the 2000s, the JCOG-LCSSG has investigated adequate modes of surgical resection for small-sized and peripheral non-small cell lung cancer and based on the radiological findings of whole tumor size and ground-glass opacity. Trials, such as JCOG0802, JCOG0804, and JCOG1211, have shown the appropriateness of sublobar resection, which has significantly influenced routine clinical practice. With the introduction of targeted therapy and immunotherapy, treatment strategies for lung cancer have changed significantly. Additionally, with the increasing aging population and medical costs, tailored medicine is strongly recommended to address medical issues. To ensure comprehensive treatment, strategies, including surgical and nonsurgical approaches, should be developed. Currently, the JCOG-LCSSG has conducted numerous clinical trials to adjust the diversity of lung cancer treatment strategies. This review highlights recent advancements in the surgical field, current status, and future direction of the JCOG-LCSSG.
日本临床肿瘤学会（JCOG）的肺癌外科研究组（LCSSG）于1986年成立，最初有26个合作机构，目前已增至52个机构。JCOG-LCSSG成员包括胸外科医生、医学肿瘤学家、病理学家和放射治疗师。早期，JCOG-LCSSG主要专注于肺癌的综合治疗。自21世纪以来，JCOG-LCSSG基于肿瘤整体大小和磨玻璃影的影像学表现，研究了小尺寸及外周型非小细胞肺癌的合适手术切除方式。JCOG0802、JCOG0804和JCOG1211等试验已证明亚肺叶切除的合理性，这对常规临床实践产生了重大影响。随着靶向治疗和免疫治疗的引入，肺癌的治疗策略发生了显著变化。此外，随着人口老龄化和医疗成本的增加，强烈建议采用精准医疗来解决医疗问题。为确保综合治疗，应制定包括手术和非手术方法在内的策略。目前，JCOG-LCSSG已开展了多项临床试验，以调整肺癌治疗策略的多样性。本综述重点介绍了JCOG-LCSSG在外科领域的最新进展、现状及未来方向。
